Penumbra (PEN)
(Delayed Data from NYSE)
$210.12 USD
+12.55 (6.35%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $209.94 -0.18 (-0.09%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PEN 210.12 +12.55(6.35%)
Will PEN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PEN
Penumbra (PEN) Tops on Q2 Earnings, Lowers Sales View
Penumbra (PEN) Reports Q2 Earnings: What Key Metrics Have to Say
PEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Penumbra (PEN) Q2 Earnings and Revenues Beat Estimates
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
Why Penumbra (PEN) is a Top Momentum Stock for the Long-Term
Other News for PEN
Baird Q2 2024 Mid Cap Growth Equity Fund Commentary
Penumbra price target raised by $22 at Citi, here's why
Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference
Penumbra Grinding Through A Painful Growth Expectations Reset
Penumbra: Growth In Its Thrombectomy Portfolio Should Lead To Strong Earnings